

**Supplemental Table 1**

<b>Variant</b>	<b>Expression Level</b>	<b>S1-Ig(301-749) Binding</b>	<b>Entry</b>
Wild-type ACE2	100	100	100
K68D	126	92	110
E110P	98	89	140
E160R	110	101	150
R192D	46	30	80
R219D	56	55	90
H228N/E231K	111	105	140
H239Q	80	60	136
Q306E	118	90	85
K309A	131	87	83
E312A	67	50	71
N338D/V339D/Q340R	90	72	95
D350A	123	89	120
P389A	118	63	91
S425P/P426S/D427N	96	83	92
K465Q/Q466D/E467K	114	87	77

**Table 1. Expression, HCoV-NL63 S1-Ig association and S-protein-mediated entry of cells expressing human ACE2 variants.** As previously reported (Li et al., 2005c), the indicated ACE2 variants do not significantly interfere with SARS-CoV S1-Ig binding or S-protein-mediated entry. Expression is measured by flow cytometry of transfected HEK293T cells using an antibody (9E10) recognizing a previously described (Li et al., 2005c) amino-terminal c-myc tag on ACE2 and variants. HCoV-NL63 S1-Ig(301-749) binding is also measured by flow cytometry using a FITC-conjugated anti-human-Fc as a secondary antibody. Entry of HCoV-NL63 S-protein pseudotyped lentivirus expressing luciferase is measured as previously described (Li et al., 2005c; Sui et al., 2005b).